AREG and metastatic colorectal cancer: In terms of EREG/AREG as a combined dichotomous biomarker, data from the PICCOLO trial confirmed that high ligand mRNA levels or IHC positivity are predictive biomarkers of benefit from panitumumab treatment in patients with metastatic colorectal cancer (Fig. 7a-c).